RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
  Autoimmune Diseases
  Immunosupressants
  Monoclonal Antibodies
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Immunology Channel

subscribe to Immunology newsletter
Latest Research : Immunology

   EMAIL   |   PRINT
Interferon gamma (IFNy) induces death of developing mast cells

Aug 25, 2005 - 3:09:00 AM
Because mast cells cause inflammation, regulating how many mast cells the body makes, where they go, what they do, and when they die can have a huge impact on health and disease.

 
[RxPG] Virginia Commonwealth University immunologists studying mast cells, known to play a central role in asthma and allergic disease, have identified a hormone-like molecule that can kill these cells by programming them to die in studies with mice.

The findings move researchers another step closer to understanding the life cycle of mast cells, and may help researchers develop new treatments for allergy and inflammatory responses in arthritis, multiple sclerosis and heart disease.

In the Journal of Immunology, published online Aug. 23, researchers demonstrated the means by which a cytokine called interferon gamma (IFNy) induces death of developing mast cells in a mouse model system. Although IFNy induced cell death in developing mast cells, it did not affect the survival of mast cells that had already undergone differentiation.

“We believe that cytokines, such as interferon gamma, are an important means of controlling mast cell function in the body,” said John J. Ryan, Ph.D., associate professor of biology at VCU and lead author of the study. “Because mast cells cause inflammation, regulating how many mast cells the body makes, where they go, what they do, and when they die can have a huge impact on health and disease.

“For example, there has been one report of a patient with mastocytosis, which is a type of pre-leukemia where mast cells proliferate abnormally, that showed improvement with IFNy treatment,” he said. “It is possible that other mast cell-related diseases, such as asthma, may respond to IFNy treatment.”

According to Ryan, mast cells are packed with granules containing histamine and are present in nearly all tissues except blood. When mast cells are activated, inflammatory substances such as histamine, heparin and a number of cytokines are rapidly released into the tissues and blood, promoting an allergic reaction.

Mast cells are believed to be generated by different precursor cells in the bone marrow. In the in vitro portion of the study, researchers used mouse bone marrow cells containing the stem cells that give rise to mast cells. They cultured these precursor cells in conditions that allow mast cells to develop, and then added IFNy to some of these cultures. A high rate of cell death yielding no living mast cells was observed in the cultures that received IFNy.

Similar results were reported in vivo using a mouse model. Mice with a mutation that causes them to overproduce IFNy were used, and again, researchers observed a significant decrease in mast cell numbers due to the excess of IFNy. When researchers tried to culture mast cells from the bone marrow of these mice, the mast cells died.

Furthermore, a separate strain of mice with the same mutation as the first strain, but that had also been engineered to prevent IFNy production, were found to have almost as many mast cells as normal mice, if not more. They concluded that the presence of high IFNy levels blocked mast cell development.

This research was supported by a grant from the National Institutes of Health.

Ryan collaborated with colleagues in the VCU Department of Biology, and the Department of Biochemistry at St. Jude Children’s Research Hospital in Memphis, Tenn.



Publication: Journal of Immunology, published online Aug. 23
On the web: Virginia Commonwealth University 

Advertise in this space for $10 per month. Contact us today.


Related Immunology News
NIH renews funding for University of Maryland vaccine research
Traffic pollution and wood smoke increases asthma in adults
82 percent of adults support banning smoking when kids are in the car
Dr. Laurie Glimcher receives the Advancing Women in Science and Medicine Award
Parents who suck on their infants' pacifiers may protect their children against developing allergy
Genetics defines a distinct liver disease
Scientists find ethnicity linked to antibodies
Bird flu mutation study offers vaccine clue
Researchers developing antiviral drug to combat contagious norovirus
Nerve damage may underlie widespread, unexplained chronic pain in children

Subscribe to Immunology Newsletter

Enter your email address:


 Additional information about the news article
About VCU and the VCU Medical Center: Located on two downtown campuses in Richmond, Va., Virginia Commonwealth University is ranked nationally by the Carnegie Foundation as a top research institution and enrolls more than 28,500 students in more than 181 certificate, undergraduate, graduate, professional and doctoral programs in the arts, sciences and humanities in 15 schools and one college. Forty of the university’s programs are unique in Virginia, and 20 graduate and professional programs have been ranked by U.S. News & World Report as among the best of their kind. MCV Hospitals, clinics and the health sciences schools of Virginia Commonwealth University compose the VCU Medical Center, one of the leading academic medical centers in the country. For more, see www.vcu.edu.
 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)